Last reviewed · How we verify

APG-1252 — Competitive Intelligence Brief

APG-1252 (APG-1252) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bcl-2/Bcl-xL inhibitor. Area: Oncology.

phase 1 Bcl-2/Bcl-xL inhibitor Bcl-2, Bcl-xL Oncology Small molecule Live · refreshed every 30 min

Target snapshot

APG-1252 (APG-1252) — Ascentage Pharma Group Inc.. APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
APG-1252 TARGET APG-1252 Ascentage Pharma Group Inc. phase 1 Bcl-2/Bcl-xL inhibitor Bcl-2, Bcl-xL
Lisaftoclax (APG-2575) Lisaftoclax (APG-2575) Ascentage Pharma Group Inc. phase 3 BCL-2/BCL-xL inhibitor BCL-2, BCL-xL
APG-2575(Lisaftoclax ) APG-2575(Lisaftoclax ) Ascentage Pharma Group Inc. phase 3 BCL-2/BCL-xL inhibitor BCL-2, BCL-xL

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bcl-2/Bcl-xL inhibitor class)

  1. Ascentage Pharma Group Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APG-1252 — Competitive Intelligence Brief. https://druglandscape.com/ci/apg-1252. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: